3月7日，再鼎医药(ZLAB)盘中上涨5.31%，截至22:55，报37.27美元/股，成交551.06万美元，总市值40.86亿美元。
财务数据显示，截至2024年12月31日，再鼎医药收入总额3.99亿美元，同比增长49.59%；归母净利润-2.57亿美元，同比增长23.17%。
大事提醒：
3月3日，再鼎医药获美国银行重申评级Neutral，目标价上调至36.1美元。
资料显示，再鼎医药有限公司是一家以患者为中心的、处于商业化阶段的创新型全球生物制药公司,立足中国、全球运营,致力于为中国及全球的患者提供针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的同类最优和同类首创药物。公司的使命是成为全球领先的生物制药公司,为中国和世界各地的患者提供变革性创新药物。再鼎医药的长期目标是成为全球领先的生物制药公司,以中国为基,为全球患者提供创新疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.